The US Food and Drug Administration (FDA) approval in December 2023, of two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of a rare disease called sickle cell disease (SCD) in patients 12 years and older, is a huge development. With rare diseases posing significant challenges due to the scarcity of information, limited research, and insufficient awareness among healthcare professionals and the public, introduction and approval of s...
First-ever installation in Fortis Hospital, Bengaluru...
American Lung Association releases report detailing health benefits for children of transition to zero-emission vehicles and electricity...
Applicable across diverse ethnic populations, including Chinese and European...
A game-changer for AD diagnosis and precision treatment...
GALI™ SonR® CRT-D and NAVIGO™ 4LV Pacing Leads Launch Set to Enhance Heart Failure Management and Patient Safety...
In a decisive vote, experts highlight the benefits of the minimally invasive device, paving the way for potential FDA approval and offering new hope to patients with limited treatment options....
OrthoDome Forum Features a Video of the Reverse HRS Hip Replacement Procedure; Presentation also Features Five-Year Radiostereometric Analysis and Patient Reported Outcome Measures of the Reverse HRS...
Trodelvy and HER-2 TriNKET combinations will be in metastatic breast cancer (mBC) and non-small cell lung cancer (NSCLC)....
Smith+Nephew Introduces AETOS◊ Shoulder System at AAOS 2024 Annual Meeting...
